BAM-15 + SLU-PP-332 Blend

The BAM-15 + SLU-PP-332 Blend is a research combination containing BAM-15, a selective mitochondrial protonophore, and SLU-PP-332, an ERRα (estrogen-related receptor alpha) agonist. This blend combines two distinct mechanisms of metabolic modulation: BAM-15 uncouples mitochondrial oxidative phosphorylation to increase substrate oxidation and energy expenditure, while SLU-PP-332 activates ERRα-dependent transcriptional programs involved in mitochondrial biogenesis and oxidative metabolism. Both compounds are non-peptide small molecules that have been independently investigated in preclinical metabolic models. The combination is designed for research examining the potential synergistic or additive effects of simultaneous mitochondrial uncoupling and nuclear receptor-mediated metabolic gene regulation. Each component targets a different node in the cellular energy metabolism network.

The BAM-SLU Melt Blend combines two complementary mechanisms of action in metabolic research. BAM-15 has been investigated for its selective protonophore activity at the inner mitochondrial membrane, facilitating proton leak that dissipates the electrochemical gradient and increases electron transport chain flux, substrate oxidation, and energy expenditure. SLU-PP-332 has been investigated for its activation of estrogen-related receptor alpha (ERRα), an orphan nuclear receptor that regulates transcription of genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation. Researchers have studied ERRα agonism for its effects on PGC-1α co-activation and OXPHOS gene expression. Studies suggest that combining acute mitochondrial uncoupling (BAM-15) with transcriptional metabolic reprogramming (SLU-PP-332) may engage complementary pathways in cellular energy metabolism, though the combination has primarily been studied in the research context rather than as established pharmacology.

BAM-15 Metabolic Effects

Alexopoulos et al. (2020) investigated BAM-15 in diet-induced obese mice and observed that oral administration was associated with reduced fat mass and improved insulin sensitivity without changes in food intake, establishing the metabolic profile of this blend component [1].

SLU-PP-332 and Exercise Mimicry

Kim et al. (2023) investigated SLU-PP-332 as an ERRα agonist in murine models. Researchers observed that treatment was associated with increased expression of oxidative muscle fiber genes and enhanced running endurance, suggesting the compound activates exercise-like transcriptional programs [2].

ERRα in Metabolic Regulation

Giguère (2008) reviewed the role of ERRα in energy metabolism, describing how this orphan nuclear receptor coordinates mitochondrial biogenesis and function across tissues with high metabolic demand, providing the rationale for ERRα agonism as a metabolic research target [3].